Physician profile
Perry Timberlake
NPI 1811159478
$555.06
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $109 · 2021: $226 · 2022: $29.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $152.05 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $134.29 | 2019-2022 | |
| Pfizer INC. | $70.19 | 2019-2021 | |
| Abbvie INC. | $50.86 | 2021 | |
| Lilly USA, LLC | $45.08 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $39.72 | 2019-2021 | |
| Abbott Laboratories | $32.63 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.91 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Timberlake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.